http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2021219828-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_87dddc054bafa69e527415f5f6f98674 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-47 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-20 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-428 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-06 |
| filingDate | 2021-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da229be061d7cbaa1b34b910a267512a http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_41664ed43324221527effeb9a6dd6587 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_979976ca08074e66193ce92abd05a389 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d7686f33ac76de0aeead3ef6def1f021 |
| publicationDate | 2021-11-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2021219828-A1 |
| titleOfInvention | New imidazolone derivatives as inhibitors of protein kinases in particular dyrk1a, clk1 and/or clk4 |
| abstract | The present invention relates to a compound of formula (I) wherein R1 represents a (C1-C6)alkyl group, a spiro(C5-C11)bicyclic ring, a fused phenyl group, a substituted phenyl group, a R'-L- group, wherein L is either a single bond or a (C1-C3)alkanediyl group, and R' represents a (C3-C8)cycloalkyl group, a bridged (C6- C10)cycloalkyl group, a (C3-C8)heterocycloalkyl group, or a (C3-C8)heteroaryl group, or a R'-L- group wherein L is a (C1-C3)alkanediyl group, and R' is an optionally substituted phenyl group, and wherein R2 represents a hydrogen atom or a (C1-C3)alkyl group or any of its pharmaceutically acceptable salt. The present invention further relates to a composition comprising a compound of formula (I) and a process for manufacturing said compound as well as its synthesis intermediates. It also relates to said compound for use as a medicament, in particular in the treatment and/or prevention of cognitive deficits associated with Down syndrome; Alzheimer's disease; dementia; tauopathies; Parkinson's disease; CDKL5 Deficiency Disorder; Phelan- McDermid syndrome; autism; type 1 and type 2 diabetes; abnormal folate and methionine metabolism; osteoarthritis; Duchenne muscular dystrophy; several cancers; neuroinflammation, anemia and viral and unicellular infections and for regulating body temperature. |
| priorityDate | 2020-04-30-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 213.